… Sacubitril/valsartan reduced the risk of CV mortality compared to standard therapy with an
ACE-I in patients with heart failure … and tolerability of sacubitril/valsartan in patients with more …

… Efficacy of sacubitril/valsartan in adult patients with chronic heart failure and reduced …
was death from cardiovascular causes or first hospitalization for worsening heart failure. CV …

… This meta-analysis evaluated the efficacy of sacubitril/valsartan compared to the RAS
inhibitors in patients with heart failure and CKD. It was found that sacubitril/valsartan significantly …

… The PARADIGM-HF trial showed that sacubitril–valsartan, an … patients with heart
failure (HF). It is uncertain what proportion of patients with HF would be eligible for sacubitril–valsartan …

… heart failure and death from cardiovascular causes. We examined clinical endpoints and the
safety of sacubitril–valsartan … in blood pressure from the end of valsartan run-in to Weeks 4 …

… Initiation of sacubitril/valsartan in hospitalized patients with heart failure with reduced
ejection fraction after hemodynamic stabilization: primary results of the TRANSITION study. …

… The therapeutic effects of sacubitril/valsartan, compared with a renin-angiotensin-… ,
particularly for heart failure hospitalization, that appear to extend to patients with heart failure and …

… the benefits and adverse effects of sacubitril/valsartan in heart failure, with a focus on … )
comparing sacubitril/valsartan versus a reference drug, in heart failure patients with reduced (…

… and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic
heart failure … with the special contribution of the Heart Failure Association (HFA) of the ESC.  …

… , patients with chronic heart failure (HF) remain at high risk for HF progression and death.
Sacubitril/valsartan (… (NEP) inhibitor (sacubitril) and an angiotensin II (Ang-II) receptor blocker (…